Download DNB 2017 Dec MED ONCO MED ONCO PAPER III Question Paper

Download Diplomate in National Board (DNB) 2017 Dec MED ONCO MED ONCO PAPER III Previous Question Papers

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017
MEDICAL ONCOLOGY
PAPER ? |||
Time :3 hours MED.ONCO./D/17/17/|l|
Max. Marks : 100
Important instructions:
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and Iegibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two
answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1.
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
a. What is metronomics in cancer care?
b.
c.
Mechanisms proposed for metronomic therapy.
Mention randomized trial based inference for and
against use of metronomic therapy in refractory
cancers.
With respect to oral cancer, describe:
a.
b.
c.
Epidemiology
Role of viral etiology
Role of targeted therapy
Epidemiology of gall bladder cancer in India
Staging of gall bladder cancer.
Role of chemotherapy in unresectable gall bladder
cancer
Diagnosis of pontine glioma
Medical management of pontine glioma including
targeted therapy
What are the domains of quality of life assessment?
Mention the tools for assessment of quality of life.
Predictors of graft versus host disease in haploidentical
transplant
Pros and cons of cord stem cell transplant versus
haploidentical transplant tor malignancies.
How is a biosimilar molecule different from a generic
molecule?
What are the trial requirement for a biosimilar agent in
India?
What is a phase IV clinical trial?
.1.
2+3+5
3+3+4
4+3+3
4+6
5+5
4+6
4+3+3
P.T.O.

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017
MEDICAL ONCOLOGY
PAPER ? Ill
8. a. Which cases of breast and ovarian cancer you would 3+2+2+3
send for genetic counseling?
b. What diagnostic tests would be performed for detecting
hereditary breast / ovarian cancer syndrome?
0. How would you plan the follow up of these patients?
d. What is the supporting evidence for prophylactic
mastectomy in this setting?
9. a. Staging system of neuroblastoma. 4+3+3
b. How is stage IVS neuroblastoma different from stage
IV neuroblastoma.
0. Targeted therapy for neuroblastoma.
10. a. Role of viral and bacterial infections in causing 4+3+3
lymphoma.
b. Treatment of an organism related lymphoma- Explain
with example.
Setting of lymphoma where only radiotherapy is used.
.0
*******
.2.
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.